Open Access Critical Evidence Review

Risk of progression to diabetes from prediabetes defined by HbA1c or fasting plasma glucose criteria - Evidence review

The Korean study observed that prediabetes defined by glycated hemoglobin, HbA1c, was associated with a greater five-year progression to diabetes compared to fasting glycemia alone. Other research confirms the prognostic value of HbA1c, but does not demonstrate that it is always superior, nor does it causally explain every underlying metabolic mechanism.

Cite this article
Iodice, D. (2026). Risk of progression to diabetes from prediabetes defined by HbA1c or fasting plasma glucose criteria - Evidence review. Life Science Hub Journal. DOI: 10.5281/zenodo.24159024. https://lifesciencehub.info/en/risk-of-progression-to-diabetes-from-prediabetes-defined-by-hba1c-or-fasting-plasma-glucose
LIFE Science Hub - Journal of Science · 2026 / Nov

DOI 10.5281/zenodo.24159024

Article history
Dates
  • Published 12/11/2026
  • Updated 12/11/2026
Revisions
  1. v1.0 — 12/11/2026 Initial publication of the article.

LIFE Science Hub keeps a record of every published version of the article to ensure editorial transparency. Future revisions will appear here.

Scientific composition with symbols of glycemic control: HbA1c, fasting glycemia, and risk of progression from prediabetes to diabetes.
Editorial photographic illustration of prediabetes as a metabolic risk: a comparison between HbA1c and fasting glycemia, with scientific and biological elements suggesting the transition toward diabetes.

ABSTRACT

The analyzed study compared, in Korean adults without baseline diabetes, the ability of glycated hemoglobin (HbA1c, an indicator of average glucose exposure over the previous months) and fasting plasma glucose to identify individuals with prediabetes who would develop diabetes over the following five years. In nearly 18,000 participants, the group identified by HbA1c showed a progression reported as higher compared to the group identified by fasting glucose.

In the chapter dedicated to HbA1c, "The Choice to Live in Health or Illness" by Dr. A. Colonnese and R. Panzironi uses this result to explain that HbA1c can recognize a population with higher metabolic vulnerability. Independent evidence confirms that higher HbA1c values are associated with a greater future risk of diabetes and that HbA1c also reflects glycemic exposure after meals. However, studies in other populations have found similar predictive capacities between HbA1c and fasting glucose. The most prudent interpretation is therefore that HbA1c adds useful prognostic information, without automatically replacing other tests.

Analyzed study

Risk of progression to diabetes from prediabetes defined by HbA1c or fasting plasma glucose criteria in Koreans

Kim CH, Kim HK, Kim EH, Bae SJ, Choe J, Park JY

Diabetes research and clinical practice, 2016

DOI: 10.1016/j.diabres.2016.06.009

PMID: 27368062

The research question was whether prediabetes identified via HbA1c or fasting plasma glycemia was associated with a different probability of developing diabetes in the medium term. The hypothesis was that these two criteria, while both describing a condition of impaired glycemia, do not necessarily select individuals with the same level of risk.

The study is relevant to the passage from "The Choice to Live in Health or Illness" by Dr. A. Colonnese and R. Panzironi, which describes HbA1c as a measure of persistent glycemic exposure and, therefore, potentially capable of identifying subjects more vulnerable to the future onset of diabetes. The publication primarily documents a prognostic association: a prediabetes classification based on HbA1c was followed by a higher frequency of diabetes compared to a classification based on fasting glycemia. However, it cannot prove that HbA1c causes diabetes, nor that it directly measures the deterioration of pancreatic beta cells or insulin resistance.

Materials and methods of the original study

A cohort of 17,971 Korean adults, aged between 20 and 79, who underwent periodic health check-ups was analyzed. The average interval between assessments was 5.2 years, with a reported range of 3.1 to 6.7 years.

Prediabetes was defined according to two criteria: fasting plasma glycemia between 5.6 and 6.9 mmol/L or HbA1c between 5.7% and 6.4%, equivalent to 39–46 mmol/mol. Incident diabetes, meaning diabetes that developed during the observation period, was defined by fasting glycemia equal to or greater than 7.0 mmol/L, HbA1c equal to or greater than 6.5%, or the initiation of antidiabetic medication.

Since the available material consists exclusively of the abstract, the detailed exclusion criteria, initial clinical characteristics of the groups, any overlap between subjects identified by the two tests, statistical adjustments, or separate analyses by age, sex, body weight, or other risk factors are not reported in the available material.

Results

At the beginning of the study, 5,495 participants, equal to 30.6% of the cohort, were classified as having prediabetes based on fasting glycemia. Using the HbA1c criterion, 3,664 participants were classified as having prediabetes, equal to 20.4%. HbA1c therefore identified a numerically smaller proportion of people compared to fasting glycemia.

Over the following five years, progression to diabetes was reported in 14.7% of subjects with prediabetes identified by HbA1c and in 10.4% of those identified by fasting glycemia. In simple terms, in the Korean cohort, the group selected by HbA1c had a frequency of subsequent diabetes diagnosis that was 4.3 percentage points higher than the group selected by fasting glycemia.

The abstract states that the difference was statistically significant, but the full P-value is truncated in the provided material. Hazard ratios (HR)—that is, the ratios between the rates at which diabetes appears in the groups—confidence intervals, or results of analyses adjusted for potential baseline differences between participants are not reported in the available material.

Interpretation

The result suggests that a measure capable of summarizing glucose exposure over time can identify, in this specific population, individuals in whom metabolic impairment is more persistent. HbA1c does not just capture a single fasting morning; it depends on the amount of glucose circulating over the previous weeks and therefore also incorporates a portion of the variations that occurred after meals.

This is the segment of the book's narrative actually supported by the study: prediabetes defined by HbA1c → higher observed frequency of diabetes in the following five years compared to prediabetes defined by fasting glycemia alone. The idea that this difference represents a progressive impairment of pancreatic beta-cell insulin secretion and an increase in insulin resistance is pathophysiologically plausible, but it was not measured directly in the analyzed study.

The data does not authorize considering HbA1c as always superior to fasting glycemia. The two tests may identify only partially overlapping groups, and their predictive capacity depends on the population, the thresholds used, conditions that modify HbA1c, and the definition adopted for incident diabetes.

Independent confirming evidence

A systematic review of 16 prospective studies, involving a total of 44,203 adults and a mean follow-up of 5.6 years, found a continuous relationship between HbA1c and the subsequent development of diabetes. In subjects with HbA1c between 5.5% and 6.0%, the five-year incidence ranged from 9% to 25%; with HbA1c equal to or greater than 6.0%, the five-year risk ranged from 25% to 50%. This evidence confirms the prognostic step in the book: a higher HbA1c identifies a greater future probability of diabetes. The review collects observational studies and does not prove that HbA1c is the cause of metabolic evolution; furthermore, some definitions of incident diabetes included glycemic markers linked to HbA1c itself [1].

An analysis using continuous glucose monitoring clarified why HbA1c can provide additional information compared to fasting glycemia alone. In 77 participants without diabetes, greater glycemic exposure after meals was associated with higher HbA1c after adjusting for potential confounding factors. The study therefore supports the intermediate step of the narrative: HbA1c also reflects postprandial glycemic components—that is, those occurring after meals—which are not detectable by a single fasting blood draw. The sample was small and the study was observational; it does not allow for directly attributing the risk of diabetes to these glycemic excursions [2].

Taken together, these independent studies reinforce the idea that HbA1c is a prognostic biomarker—that is, an indicator associated with the likely future course—and that it synthesizes aspects of daily glycemia different from those captured by fasting measurements alone. Confirmation of the link with beta-cell function and insulin resistance, however, remains predominantly indirect.

Conflicting evidence

A large Japanese cohort provided results less favorable to the idea of a clear superiority of HbA1c. In 6,241 adults without diabetes followed for an average of 4.7 years, the progression to diabetes among those who had prediabetes identified only by HbA1c was 7%, compared to 9% among those who had prediabetes identified only by fasting glycemia; the difference was not statistically significant. After adjustment, both criteria were associated with a strong increase in risk compared to normoglycemia: HR 6.00 for isolated HbA1c and HR 6.16 for isolated fasting glycemia [3].

This study does not contradict the fact that HbA1c can signal an increased risk. However, it scales back the comparative claim that it always identifies a more vulnerable population than fasting glycemia. The concordance between the two tests was incomplete, and the highest risk was observed when both criteria were present. The differences between the Japanese and Korean cohorts may depend on the population, period, definitions, and baseline metabolic characteristics.

Summary table of evidence

The table distinguishes the publication subject to the review from the independent research used to confirm or define the narrative of the book's paragraph.

Reference Study type Population or model Main result Direction of evidence Strength of evidence
Original study Prospective cohort 17,971 Korean adults, followed for an average of 5.2 years Prediabetes defined by HbA1c showed a 14.7% progression to diabetes, compared to 10.4% using the fasting glycemia criterion. direct confirmation moderate
[1] Systematic review of prospective cohorts 44,203 adults across 16 studies As HbA1c increased, the subsequent risk of diabetes increased; HbA1c ≥6.0% was associated with a 25% to 50% five-year risk. direct confirmation moderate
[2] Observational with continuous glucose monitoring 77 people without diabetes and groups with type 2 diabetes In people without diabetes, higher postprandial glycemic exposure was associated with higher HbA1c. biologically consistent evidence preliminary
[3] Longitudinal cohort 6,241 Japanese adults without initial diabetes HbA1c and fasting glycemia in isolation showed similar risk increases; the combination of the two criteria identified the highest risk. discordant evidence moderate

Confirmation of the evidence

Claim in the book

In the section on glycated hemoglobin, “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi states that individuals classified with prediabetes via HbA1c showed a higher probability of progressing to diabetes compared to those identified solely by fasting glycemia. The text interprets this data as consistent with the ability of HbA1c to integrate daily glycemic fluctuations, including postprandial ones, and to represent a persistent metabolic vulnerability.

Repeated glycemic exposure, including postprandial → higher HbA1c → identification of prediabetes → greater observed probability of future diabetes

The publication subject to the Evidence Review was used in the book to support the following passage: in the Korean cohort, prediabetes defined by HbA1c identified a smaller proportion of people, but with a higher observed frequency of progression to diabetes compared to prediabetes defined by fasting plasma glycemia alone.

The correspondence between the original publication and the paragraph is direct in terms of prognosis: the central result reported is precisely the greater five-year progression to diabetes in the group defined by HbA1c. The systematic review by Zhang et al. confirms, in multiple independent cohorts, that the risk of diabetes increases progressively with HbA1c [1]. Furthermore, the study using continuous glucose monitoring provides a biologically consistent explanation for the reference to post-meal excursions: in people without diabetes, greater postprandial exposure was associated with higher HbA1c [2].

However, the literature does not uniformly confirm that HbA1c is always more predictive than fasting glycemia. In the Japanese cohort by Heianza et al., the two isolated criteria showed similar future risks, while the combination of the tests identified the highest-risk profile [3]. For this reason, in the context of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, the most robust formulation is that HbA1c can add a complementary prognostic perspective, not that it universally replaces or surpasses fasting glycemia.

Overall level of confirmation

MODERATE CONFIRMATION

The prognostic link is documented directly in the original study and confirmed by a meta-analysis. The explanation regarding postprandial glycemic excursions is biologically consistent, but the progression from elevated HbA1c to beta-cell impairment and insulin resistance is not directly demonstrated by the analyzed publication. Furthermore, independent cohorts show similar predictive performance between HbA1c and fasting glycemia.

Conclusions

The study analyzed directly supports the finding that, in the Korean cohort examined, prediabetes defined by HbA1c was associated with a higher observed progression to diabetes compared to prediabetes defined by fasting glycemia alone. The prognostic value of HbA1c is confirmed by independent evidence, and its link to postprandial glycemic exposure is biologically plausible. However, it remains necessary to avoid a generalized conclusion of HbA1c superiority: the tests identify different and complementary profiles, and their performance varies across populations and clinical settings.

Overall assessment

The narrative is moderately supported. HbA1c is well-supported as a biomarker associated with an increased future risk of diabetes and as an indicator of prolonged glycemia, including a postprandial component. Its alleged superiority over fasting glycemia, however, remains population-dependent and requires complementary interpretation.

References

[1] A1C Level and Future Risk of Diabetes: A Systematic Review

Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W, Bullard KM, et al., 2010

Diabetes Care

[2] Relative contributions of preprandial and postprandial glucose exposures, glycemic variability, and non-glycemic factors to HbA 1c in individuals with and without diabetes

Færch K, Alssema M, Mela DJ, Borg R, Vistisen D, 2018

Nutrition & Diabetes

[3] HbA1c 5·7–6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study

Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, Tsuji H, et al., 2011

The Lancet

Editorial note

Artificial Intelligence was used solely as a tool to support editorial and documentary work. All content, interpretations, bibliographic citations and conclusions have been verified, reviewed and approved by the author, who assumes full scientific responsibility for them.

The manuscript was also subject to independent peer review prior to publication.

To ensure maximum transparency, the article's complete history — including the dates of submission, review, acceptance and publication, as well as information on the peer review process — is available on the dedicated Article History page.